[{"orgOrder":0,"company":"SRI International","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"SRI International","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"SRI International \/ Janssen Pharmaceutica","highestDevelopmentStatusID":"3","companyTruncated":"SRI International \/ Janssen Pharmaceutica"},{"orgOrder":0,"company":"SRI International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"3,4,3-Li(1,2-hopo)","moa":"","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"SRI International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SRI International \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SRI International \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by SRI International

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : HOPO 14-1 (3,4,3-Li(1,2-hopo) is a novel orally administered experimental drug, designed to act as a defence against radioactive threats and is being investigated to treat radioactive contamination in the body.

                          Brand Name : HOPO 14-1

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 15, 2023

                          Lead Product(s) : 3,4,3-Li(1,2-hopo)

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the terms of the agreement, the organizations and their scientists will leverage SRI’s SynFini™ platform, an artificial intelligence (Al)-guided, automated synthetic- chemistry system for small molecule drug discovery.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 05, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : Johnson & Johnson Innovative Medicine

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank